<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298023</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-ASC_TR</org_study_id>
    <nct_id>NCT02298023</nct_id>
  </id_info>
  <brief_title>Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)</brief_title>
  <official_title>Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main purpose of this study is to evaluate efficacy of allogenic adipose-derived mesenchymal&#xD;
      stem cells in treatment of tendon injury. ALLO-ASC will be administrated to the patients with&#xD;
      supraspinatus partial thickness tear by ultrasonographic guided injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Injection volume depends on the size of lesion on ultrasound examination. And all injection&#xD;
      will be done under ultrasound guidance. Double blind Randomized placebo controlled study will&#xD;
      be done with following 3 groups. Each group will have 8 people, so, the total patients will&#xD;
      be 24 people.&#xD;
&#xD;
        1. Stem cell treatment group : stem cell 0.5cc (Total: 10 million cells) + Fibrin glue&#xD;
           0.5cc + range of motion exercise&#xD;
&#xD;
        2. Active control (fibrin glue) group : Normal saline 0.5cc + Fibrin glue 0.5cc + range of&#xD;
           motion exercise&#xD;
&#xD;
        3. Control (normal saline) group : Normal saline 0.5cc + Normal saline 0.5cc + range of&#xD;
           motion exercise&#xD;
&#xD;
      The investigators will compare the efficacy difference with VAS(visual analog scale, primary&#xD;
      outcome), ASES(American Shoulder and Elbow Surgeons) Score, UCLA(University of California,&#xD;
      Los Angles) Shoulder Score, DASH(The Disabilities of the Arm, Shoulder and Hand) Score and&#xD;
      change of tear size compared to the baseline image assessed by MRI. These measurement will be&#xD;
      done at 6 and 12 weeks after injections and long-term follow-up will be also planned to 6&#xD;
      months, 12months and 24 months except for the evaluation of the tear size which will be done&#xD;
      at baseline, 3 months and 24 months after the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Pain During Activity From Baseline to 3 Months After Intervention</measure>
    <time_frame>Baseline and 3 months after intervention</time_frame>
    <description>Pain during activity will be evaluated by visual analog scale (active pain VAS). The active pain visual analog scale change from baseline to 3 months after intervention is the primary outcome. Visual analog scale is scored 0 to 10, higher scored meaning worse outcome. Negative values in change of pain during activity indicate improvement in pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain During Rest</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
    <description>Pain during rest assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain During Activity</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
    <description>Pain during activity assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Shoulder and Elbow Surgeons (ASES) Shoulder Score</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
    <description>Functional score of the shoulder was assessed by American Shoulder and Elbow Surgeons shoulder score which is a questionnaire dedicated to the functional evaluation of the shoulder. It is scored from 0 to 100, higher scores meaning better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability of Arm, Shoulder and Hand (DASH) Score</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
    <description>Shoulder function is assessed by DASH score which is questionnaire dedicated to evaluate the function of the upper extremity. It is scored from 0 (no disability) to 100 (most severe disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of California, Los Angeles(UCLA) Shoulder Score</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
    <description>Shoulder function is assessed by UCLA shoulder score which is a composite of range of motion examination and questionnaire dedicated to evaluate the function of the shoulder. It is scored from 0 to 35, higher scores meaning better shoulder function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Size at 3 Months After Injection</measure>
    <time_frame>baseline and 3 months after intervention</time_frame>
    <description>Tear size was evaluated by 3-point Likert scale using MRI. The 3months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Size at 12 Months After Injection</measure>
    <time_frame>baseline and12 months after intervention</time_frame>
    <description>Tear size was evaluated by 3-point Likert scale using MRI. The 12 months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Rotator Cuff Tear</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active control (fibrin glue) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received fibrin glue and normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (normal saline )group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Received only normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogenic adipose stem cell injection</intervention_name>
    <description>Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.</description>
    <arm_group_label>Mesenchymal stem cell group</arm_group_label>
    <other_name>experimental group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>fibrin glue/normal saline injection</intervention_name>
    <description>Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise</description>
    <arm_group_label>Active control (fibrin glue) group</arm_group_label>
    <other_name>active control group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>normal saline injection</intervention_name>
    <description>Total 1cc of normal saline injection and range of motion exercise</description>
    <arm_group_label>Control (normal saline )group</arm_group_label>
    <other_name>placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinically diagnosed as rotator cuff tear (supraspinatus partial thickness tear)&#xD;
&#xD;
          -  recurrent pain in spite of conservative treatment such as physical therapy,&#xD;
             medication, steroid injection&#xD;
&#xD;
          -  symptom duration is over 3 months&#xD;
&#xD;
          -  supraspinatus partial thickness tear proven ultrasonography and magnetic resonance&#xD;
             image(MRI)&#xD;
&#xD;
          -  patient that can understand the clinical trials&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient that underwent other injection treatment within 6 weeks&#xD;
&#xD;
          -  some associated diseases (adhesive capsulitis, full thickness supraspinatus tear,.&#xD;
             arthritis of related joint to the target lesion, muscle weakness or atrophy,&#xD;
             innervated by suprascapular nerve, paralysis of related joint to target lesion,&#xD;
             proximal humeral fracture, infectious disease, bilateral rotator cuff tear,&#xD;
             generalized pain syndrome, radiculopathy, rheumatoid arthritis, impaired sensibility,&#xD;
             dementia, history of allergic or hypersensitive reaction to bovine-derived proteins or&#xD;
             fibrin glue and contraindication to MRI&#xD;
&#xD;
          -  patient that enrolled other clinical trials within 30 days&#xD;
&#xD;
          -  history of drug/alcohol addiction, habitual smoker, operation, allergic reaction to&#xD;
             fibrin glue, local anesthetics and bovine-derived proteins and severe medical disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Gun Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Isaac C, Gharaibeh B, Witt M, Wright VJ, Huard J. Biologic approaches to enhance rotator cuff healing after injury. J Shoulder Elbow Surg. 2012 Feb;21(2):181-90. doi: 10.1016/j.jse.2011.10.004. Review.</citation>
    <PMID>22244061</PMID>
  </reference>
  <reference>
    <citation>Müller SA, Todorov A, Heisterbach PE, Martin I, Majewski M. Tendon healing: an overview of physiology, biology, and pathology of tendon healing and systematic review of state of the art in tendon bioengineering. Knee Surg Sports Traumatol Arthrosc. 2015 Jul;23(7):2097-105. doi: 10.1007/s00167-013-2680-z. Epub 2013 Sep 21. Review.</citation>
    <PMID>24057354</PMID>
  </reference>
  <reference>
    <citation>Tashjian RZ. Epidemiology, natural history, and indications for treatment of rotator cuff tears. Clin Sports Med. 2012 Oct;31(4):589-604. doi: 10.1016/j.csm.2012.07.001. Epub 2012 Aug 30. Review.</citation>
    <PMID>23040548</PMID>
  </reference>
  <reference>
    <citation>Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi: 10.1016/S0140-6736(10)61160-9. Epub 2010 Oct 21. Review.</citation>
    <PMID>20970844</PMID>
  </reference>
  <reference>
    <citation>Sánchez M, Azofra J, Anitua E, Andía I, Padilla S, Santisteban J, Mujika I. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc. 2003 Oct;35(10):1648-52.</citation>
    <PMID>14523300</PMID>
  </reference>
  <reference>
    <citation>Price R, Sinclair H, Heinrich I, Gibson T. Local injection treatment of tennis elbow--hydrocortisone, triamcinolone and lignocaine compared. Br J Rheumatol. 1991 Feb;30(1):39-44.</citation>
    <PMID>1991216</PMID>
  </reference>
  <reference>
    <citation>Sölveborn SA, Buch F, Mallmin H, Adalberth G. Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow). Clin Orthop Relat Res. 1995 Jul;(316):99-105.</citation>
    <PMID>7634730</PMID>
  </reference>
  <reference>
    <citation>Johnson GW, Cadwallader K, Scheffel SB, Epperly TD. Treatment of lateral epicondylitis. Am Fam Physician. 2007 Sep 15;76(6):843-8. Review.</citation>
    <PMID>17910298</PMID>
  </reference>
  <reference>
    <citation>Maffulli N, Longo UG, Denaro V. Novel approaches for the management of tendinopathy. J Bone Joint Surg Am. 2010 Nov 3;92(15):2604-13. doi: 10.2106/JBJS.I.01744. Review.</citation>
    <PMID>21048180</PMID>
  </reference>
  <reference>
    <citation>Arce G, Bak K, Bain G, Calvo E, Ejnisman B, Di Giacomo G, Gutierrez V, Guttmann D, Itoi E, Ben Kibler W, Ludvigsen T, Mazzocca A, de Castro Pochini A, Savoie F 3rd, Sugaya H, Uribe J, Vergara F, Willems J, Yoo YS, McNeil JW 2nd, Provencher MT. Management of disorders of the rotator cuff: proceedings of the ISAKOS upper extremity committee consensus meeting. Arthroscopy. 2013 Nov;29(11):1840-50. doi: 10.1016/j.arthro.2013.07.265. Epub 2013 Sep 13.</citation>
    <PMID>24041864</PMID>
  </reference>
  <reference>
    <citation>Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006 Nov;34(11):1774-8. Epub 2006 May 30.</citation>
    <PMID>16735582</PMID>
  </reference>
  <reference>
    <citation>Kon E, Filardo G, Delcogliano M, Presti ML, Russo A, Bondi A, Di Martino A, Cenacchi A, Fornasari PM, Marcacci M. Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. Injury. 2009 Jun;40(6):598-603. doi: 10.1016/j.injury.2008.11.026. Epub 2009 Apr 19.</citation>
    <PMID>19380129</PMID>
  </reference>
  <reference>
    <citation>Sánchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 2007 Feb;35(2):245-51. Epub 2006 Nov 12.</citation>
    <PMID>17099241</PMID>
  </reference>
  <reference>
    <citation>Slater M, Patava J, Kingham K, Mason RS. Involvement of platelets in stimulating osteogenic activity. J Orthop Res. 1995 Sep;13(5):655-63.</citation>
    <PMID>7472743</PMID>
  </reference>
  <reference>
    <citation>Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010 Feb;38(2):255-62. doi: 10.1177/0363546509355445.</citation>
    <PMID>20448192</PMID>
  </reference>
  <reference>
    <citation>Randelli P, Arrigoni P, Ragone V, Aliprandi A, Cabitza P. Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up. J Shoulder Elbow Surg. 2011 Jun;20(4):518-28. doi: 10.1016/j.jse.2011.02.008.</citation>
    <PMID>21570659</PMID>
  </reference>
  <reference>
    <citation>Randelli PS, Arrigoni P, Cabitza P, Volpi P, Maffulli N. Autologous platelet rich plasma for arthroscopic rotator cuff repair. A pilot study. Disabil Rehabil. 2008;30(20-22):1584-9. doi: 10.1080/09638280801906081.</citation>
    <PMID>18608363</PMID>
  </reference>
  <reference>
    <citation>Mizuno H. Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J Nippon Med Sch. 2009 Apr;76(2):56-66. Review.</citation>
    <PMID>19443990</PMID>
  </reference>
  <reference>
    <citation>Casteilla L, Planat-Benard V, Laharrague P, Cousin B. Adipose-derived stromal cells: Their identity and uses in clinical trials, an update. World J Stem Cells. 2011 Apr 26;3(4):25-33. doi: 10.4252/wjsc.v3.i4.25.</citation>
    <PMID>21607134</PMID>
  </reference>
  <reference>
    <citation>Uysal AC, Mizuno H. Tendon regeneration and repair with adipose derived stem cells. Curr Stem Cell Res Ther. 2010 Jun;5(2):161-7. Review.</citation>
    <PMID>19941450</PMID>
  </reference>
  <reference>
    <citation>Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy. 2003;5(5):362-9. Review.</citation>
    <PMID>14578098</PMID>
  </reference>
  <reference>
    <citation>Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002 Dec;13(12):4279-95.</citation>
    <PMID>12475952</PMID>
  </reference>
  <reference>
    <citation>Mizuno H, Hyakusoku H. Mesengenic potential and future clinical perspective of human processed lipoaspirate cells. J Nippon Med Sch. 2003 Aug;70(4):300-6. Review.</citation>
    <PMID>12928709</PMID>
  </reference>
  <reference>
    <citation>von Heimburg D, Hemmrich K, Haydarlioglu S, Staiger H, Pallua N. Comparison of viable cell yield from excised versus aspirated adipose tissue. Cells Tissues Organs. 2004;178(2):87-92.</citation>
    <PMID>15604532</PMID>
  </reference>
  <reference>
    <citation>Smith RK, Webbon PM. Harnessing the stem cell for the treatment of tendon injuries: heralding a new dawn? Br J Sports Med. 2005 Sep;39(9):582-4.</citation>
    <PMID>16118291</PMID>
  </reference>
  <reference>
    <citation>Chong AK, Ang AD, Goh JC, Hui JH, Lim AY, Lee EH, Lim BH. Bone marrow-derived mesenchymal stem cells influence early tendon-healing in a rabbit achilles tendon model. J Bone Joint Surg Am. 2007 Jan;89(1):74-81.</citation>
    <PMID>17200313</PMID>
  </reference>
  <reference>
    <citation>Ouyang HW, Goh JC, Thambyah A, Teoh SH, Lee EH. Knitted poly-lactide-co-glycolide scaffold loaded with bone marrow stromal cells in repair and regeneration of rabbit Achilles tendon. Tissue Eng. 2003 Jun;9(3):431-9.</citation>
    <PMID>12857411</PMID>
  </reference>
  <reference>
    <citation>Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL. Effect of adipose-derived nucleated cell fractions on tendon repair in horses with collagenase-induced tendinitis. Am J Vet Res. 2008 Jul;69(7):928-37. doi: 10.2460/ajvr.69.7.928.</citation>
    <PMID>18593247</PMID>
  </reference>
  <reference>
    <citation>Gulotta LV, Kovacevic D, Ehteshami JR, Dagher E, Packer JD, Rodeo SA. Application of bone marrow-derived mesenchymal stem cells in a rotator cuff repair model. Am J Sports Med. 2009 Nov;37(11):2126-33. doi: 10.1177/0363546509339582. Epub 2009 Aug 14.</citation>
    <PMID>19684297</PMID>
  </reference>
  <reference>
    <citation>Del Bue M, Riccò S, Ramoni R, Conti V, Gnudi G, Grolli S. Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo. Vet Res Commun. 2008 Sep;32 Suppl 1:S51-5. doi: 10.1007/s11259-008-9093-3.</citation>
    <PMID>18683070</PMID>
  </reference>
  <reference>
    <citation>Ellera Gomes JL, da Silva RC, Silla LM, Abreu MR, Pellanda R. Conventional rotator cuff repair complemented by the aid of mononuclear autologous stem cells. Knee Surg Sports Traumatol Arthrosc. 2012 Feb;20(2):373-7. doi: 10.1007/s00167-011-1607-9. Epub 2011 Jul 20.</citation>
    <PMID>21773831</PMID>
  </reference>
  <reference>
    <citation>MacIsaac ZM, Shang H, Agrawal H, Yang N, Parker A, Katz AJ. Long-term in-vivo tumorigenic assessment of human culture-expanded adipose stromal/stem cells. Exp Cell Res. 2012 Feb 15;318(4):416-23. doi: 10.1016/j.yexcr.2011.12.002. Epub 2011 Dec 13.</citation>
    <PMID>22185824</PMID>
  </reference>
  <reference>
    <citation>Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012 May;27(5):595-600. doi: 10.1007/s00384-011-1350-1. Epub 2011 Nov 9.</citation>
    <PMID>22065114</PMID>
  </reference>
  <reference>
    <citation>Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study. Equine Vet J. 2008 Mar;40(2):178-81. doi: 10.2746/042516408X276942.</citation>
    <PMID>18267891</PMID>
  </reference>
  <reference>
    <citation>Shiri R, Viikari-Juntura E, Varonen H, Heliövaara M. Prevalence and determinants of lateral and medial epicondylitis: a population study. Am J Epidemiol. 2006 Dec 1;164(11):1065-74. Epub 2006 Sep 12.</citation>
    <PMID>16968862</PMID>
  </reference>
  <reference>
    <citation>Hohendorff B, Siepen W, Spiering L, Staub L, Schmuck T, Boss A. Long-term results after operatively treated Achilles tendon rupture: fibrin glue versus suture. J Foot Ankle Surg. 2008 Sep-Oct;47(5):392-9. doi: 10.1053/j.jfas.2008.05.006. Epub 2008 Jul 14.</citation>
    <PMID>18725118</PMID>
  </reference>
  <reference>
    <citation>Minagawa H, Yamamoto N, Abe H, Fukuda M, Seki N, Kikuchi K, Kijima H, Itoi E. Prevalence of symptomatic and asymptomatic rotator cuff tears in the general population: From mass-screening in one village. J Orthop. 2013 Feb 26;10(1):8-12. doi: 10.1016/j.jor.2013.01.008. eCollection 2013.</citation>
    <PMID>24403741</PMID>
  </reference>
  <reference>
    <citation>Jo CH, Shin JS, Lee YG, Shin WH, Kim H, Lee SY, Yoon KS, Shin S. Platelet-rich plasma for arthroscopic repair of large to massive rotator cuff tears: a randomized, single-blind, parallel-group trial. Am J Sports Med. 2013 Oct;41(10):2240-8. doi: 10.1177/0363546513497925. Epub 2013 Aug 6.</citation>
    <PMID>23921338</PMID>
  </reference>
  <reference>
    <citation>Oh JH, Chung SW, Kim SH, Chung JY, Kim JY. 2013 Neer Award: Effect of the adipose-derived stem cell for the improvement of fatty degeneration and rotator cuff healing in rabbit model. J Shoulder Elbow Surg. 2014 Apr;23(4):445-55. doi: 10.1016/j.jse.2013.07.054. Epub 2013 Oct 12.</citation>
    <PMID>24129058</PMID>
  </reference>
  <reference>
    <citation>Buchbinder R, Green SE, Struijs P. Tennis elbow. BMJ Clin Evid. 2008 May 28;2008. pii: 1117. Review.</citation>
    <PMID>19450309</PMID>
  </reference>
  <reference>
    <citation>Levin D, Nazarian LN, Miller TT, O'Kane PL, Feld RI, Parker L, McShane JM. Lateral epicondylitis of the elbow: US findings. Radiology. 2005 Oct;237(1):230-4. Epub 2005 Aug 18.</citation>
    <PMID>16118152</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <results_first_submitted>June 11, 2020</results_first_submitted>
  <results_first_submitted_qc>June 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Sun Gun Chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adipose derived mesenchymal stem cell</keyword>
  <keyword>allogeneic stem cell</keyword>
  <keyword>Rotator cuff tear</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
    <mesh_term>Tendon Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment flyers were posted in a tertiary hospital and volunteers were recruited between September 2014 and April 2016. The first participant was enrolled on January 13, 2015 and the last participant was enrolled in April 12. 2016.</recruitment_details>
      <pre_assignment_details>Volunteers were screened by a experienced physiatrist prior to enrollment. Of 26 potential participants, one refused to participate and another had incompatible findings in the baseline MRI. As a result, 24 participants met the inclusion/exclusion criteria and were enrolled and randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mesenchymal Stem Cell Group</title>
          <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.&#xD;
allogenic adipose stem cell injection: Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.&#xD;
Eight participants were assigned and one declined to participate before the intervention.</description>
        </group>
        <group group_id="P2">
          <title>Active Control (Fibrin Glue) Group</title>
          <description>Received fibrin glue and normal saline.&#xD;
fibrin glue/normal saline injection: Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise&#xD;
Eight participants were assigned and followed up throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Control (Normal Saline )Group</title>
          <description>Received only normal saline.&#xD;
normal saline injection: Total 1cc of normal saline injection and range of motion exercise&#xD;
Eight participants were assigned and followed up throughout the study except one who missed the last visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intervention</title>
              <participants_list>
                <participants group_id="P1" count="7">Withdrawal by participant before intervention.</participants>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mesenchymal Stem Cell Group</title>
          <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.&#xD;
allogenic adipose stem cell injection: Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.</description>
        </group>
        <group group_id="B2">
          <title>Active Control (Fibrin Glue) Group</title>
          <description>Received fibrin glue and normal saline.&#xD;
fibrin glue/normal saline injection: Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise</description>
        </group>
        <group group_id="B3">
          <title>Control (Normal Saline )Group</title>
          <description>Received only normal saline.&#xD;
normal saline injection: Total 1cc of normal saline injection and range of motion exercise</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="7.8"/>
                    <measurement group_id="B2" value="50.4" spread="4.6"/>
                    <measurement group_id="B3" value="54.1" spread="9.4"/>
                    <measurement group_id="B4" value="54.9" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain during activity</title>
          <description>Visual Analog Scale, scored from 0 to 10, higher score meaning worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="1.6"/>
                    <measurement group_id="B2" value="4.7" spread="2.6"/>
                    <measurement group_id="B3" value="6.6" spread="2.4"/>
                    <measurement group_id="B4" value="5.7" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain during rest</title>
          <description>Visual Analog Scale, scored from 0 to 10, higher score meaning worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="1.8"/>
                    <measurement group_id="B2" value="2.4" spread="2.3"/>
                    <measurement group_id="B3" value="3.6" spread="1.8"/>
                    <measurement group_id="B4" value="3.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Shoulder and Elbow Surgeons (ASES) Shoulder Score</title>
          <description>American Shoulder and Elbow Surgeons score, scored from 0 to 100, with higher scores indicating better outcomes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="12.1"/>
                    <measurement group_id="B2" value="64.7" spread="12.8"/>
                    <measurement group_id="B3" value="54.7" spread="20.1"/>
                    <measurement group_id="B4" value="59.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>University of California, Los Angeles(UCLA) Shoulder Score</title>
          <description>University of California, Los Angeles(UCLA) Shoulder Score, range from 0 to 35 with a score of 0 indicating worse shoulder function and 35 indicating better shoulder function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="3.7"/>
                    <measurement group_id="B2" value="19.0" spread="3.4"/>
                    <measurement group_id="B3" value="17.5" spread="3.0"/>
                    <measurement group_id="B4" value="17.9" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The Disabilities of the Arm, Shoulder and Hand(DASH) Score</title>
          <description>The Disabilities of the Arm, Shoulder and Hand(DASH) Score, scored 0 to 100, lower score meaning better outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="13.0"/>
                    <measurement group_id="B2" value="35.2" spread="16.1"/>
                    <measurement group_id="B3" value="37.6" spread="23.8"/>
                    <measurement group_id="B4" value="35.1" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Pain During Activity From Baseline to 3 Months After Intervention</title>
        <description>Pain during activity will be evaluated by visual analog scale (active pain VAS). The active pain visual analog scale change from baseline to 3 months after intervention is the primary outcome. Visual analog scale is scored 0 to 10, higher scored meaning worse outcome. Negative values in change of pain during activity indicate improvement in pain.</description>
        <time_frame>Baseline and 3 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.&#xD;
allogenic adipose stem cell injection: Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.&#xD;
Eight participants were assigned and one declined to participate before the intervention.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.&#xD;
fibrin glue/normal saline injection: Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise&#xD;
Eight participants were assigned and followed up throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.&#xD;
normal saline injection: Total 1cc of normal saline injection and range of motion exercise&#xD;
Eight participants were assigned and followed up throughout the study except one who missed the last visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Pain During Activity From Baseline to 3 Months After Intervention</title>
          <description>Pain during activity will be evaluated by visual analog scale (active pain VAS). The active pain visual analog scale change from baseline to 3 months after intervention is the primary outcome. Visual analog scale is scored 0 to 10, higher scored meaning worse outcome. Negative values in change of pain during activity indicate improvement in pain.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.9"/>
                    <measurement group_id="O2" value="-1.5" spread="2.4"/>
                    <measurement group_id="O3" value="-3.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the three groups. Statistical power: 0.80</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain During Rest</title>
        <description>Pain during rest assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain During Rest</title>
          <description>Pain during rest assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.8"/>
                    <measurement group_id="O2" value="2.4" spread="2.3"/>
                    <measurement group_id="O3" value="3.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.1"/>
                    <measurement group_id="O2" value="2.2" spread="2.0"/>
                    <measurement group_id="O3" value="3.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.7"/>
                    <measurement group_id="O2" value="1.9" spread="1.7"/>
                    <measurement group_id="O3" value="2.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.9"/>
                    <measurement group_id="O2" value="1.4" spread="1.3"/>
                    <measurement group_id="O3" value="2.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="3.5"/>
                    <measurement group_id="O2" value="1.8" spread="2.4"/>
                    <measurement group_id="O3" value="1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.2"/>
                    <measurement group_id="O2" value="0.8" spread="1.3"/>
                    <measurement group_id="O3" value="0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To test whether there were differences in the rate of change among groups</non_inferiority_desc>
            <p_value>0.662</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain During Activity</title>
        <description>Pain during activity assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome</description>
        <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain During Activity</title>
          <description>Pain during activity assessed by visual analog scale (VAS), scored 0 to 10, higher scores meaning worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="1.6"/>
                    <measurement group_id="O2" value="4.7" spread="2.6"/>
                    <measurement group_id="O3" value="6.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.9"/>
                    <measurement group_id="O2" value="3.2" spread="2.1"/>
                    <measurement group_id="O3" value="4.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.9"/>
                    <measurement group_id="O2" value="3.2" spread="1.6"/>
                    <measurement group_id="O3" value="3.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.7"/>
                    <measurement group_id="O2" value="2.8" spread="2.3"/>
                    <measurement group_id="O3" value="4.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.7"/>
                    <measurement group_id="O2" value="3.2" spread="2.3"/>
                    <measurement group_id="O3" value="3.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.0"/>
                    <measurement group_id="O2" value="3.2" spread="2.1"/>
                    <measurement group_id="O3" value="1.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To test whether there were differences in the rate of change among groups</non_inferiority_desc>
            <p_value>0.882</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American Shoulder and Elbow Surgeons (ASES) Shoulder Score</title>
        <description>Functional score of the shoulder was assessed by American Shoulder and Elbow Surgeons shoulder score which is a questionnaire dedicated to the functional evaluation of the shoulder. It is scored from 0 to 100, higher scores meaning better outcome.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>American Shoulder and Elbow Surgeons (ASES) Shoulder Score</title>
          <description>Functional score of the shoulder was assessed by American Shoulder and Elbow Surgeons shoulder score which is a questionnaire dedicated to the functional evaluation of the shoulder. It is scored from 0 to 100, higher scores meaning better outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="12.1"/>
                    <measurement group_id="O2" value="64.7" spread="12.8"/>
                    <measurement group_id="O3" value="54.7" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="21.0"/>
                    <measurement group_id="O2" value="70.6" spread="19.9"/>
                    <measurement group_id="O3" value="65.9" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="17.7"/>
                    <measurement group_id="O2" value="73.7" spread="15.3"/>
                    <measurement group_id="O3" value="63.6" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" spread="19.6"/>
                    <measurement group_id="O2" value="76.7" spread="12.7"/>
                    <measurement group_id="O3" value="63.9" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" spread="23.5"/>
                    <measurement group_id="O2" value="76.0" spread="20.3"/>
                    <measurement group_id="O3" value="74.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="20.3"/>
                    <measurement group_id="O2" value="80.0" spread="16.1"/>
                    <measurement group_id="O3" value="89.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To test whether there were differences in the rate of change among groups</non_inferiority_desc>
            <p_value>0.835</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disability of Arm, Shoulder and Hand (DASH) Score</title>
        <description>Shoulder function is assessed by DASH score which is questionnaire dedicated to evaluate the function of the upper extremity. It is scored from 0 (no disability) to 100 (most severe disability).</description>
        <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Disability of Arm, Shoulder and Hand (DASH) Score</title>
          <description>Shoulder function is assessed by DASH score which is questionnaire dedicated to evaluate the function of the upper extremity. It is scored from 0 (no disability) to 100 (most severe disability).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="13.0"/>
                    <measurement group_id="O2" value="35.2" spread="16.1"/>
                    <measurement group_id="O3" value="37.6" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="15.1"/>
                    <measurement group_id="O2" value="25.8" spread="16.9"/>
                    <measurement group_id="O3" value="28.1" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="15.0"/>
                    <measurement group_id="O2" value="19.2" spread="14.1"/>
                    <measurement group_id="O3" value="28.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="14.9"/>
                    <measurement group_id="O2" value="19.8" spread="11.1"/>
                    <measurement group_id="O3" value="27.1" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="20.8"/>
                    <measurement group_id="O2" value="20.5" spread="16.2"/>
                    <measurement group_id="O3" value="20.3" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="8.9"/>
                    <measurement group_id="O2" value="22.8" spread="16.8"/>
                    <measurement group_id="O3" value="20.1" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To test whether there were differences in the rate of change among groups</non_inferiority_desc>
            <p_value>0.977</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>University of California, Los Angeles(UCLA) Shoulder Score</title>
        <description>Shoulder function is assessed by UCLA shoulder score which is a composite of range of motion examination and questionnaire dedicated to evaluate the function of the shoulder. It is scored from 0 to 35, higher scores meaning better shoulder function.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks, 6, 12, 24 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>University of California, Los Angeles(UCLA) Shoulder Score</title>
          <description>Shoulder function is assessed by UCLA shoulder score which is a composite of range of motion examination and questionnaire dedicated to evaluate the function of the shoulder. It is scored from 0 to 35, higher scores meaning better shoulder function.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="3.7"/>
                    <measurement group_id="O2" value="19.0" spread="3.4"/>
                    <measurement group_id="O3" value="17.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" spread="6.4"/>
                    <measurement group_id="O2" value="22.3" spread="6.2"/>
                    <measurement group_id="O3" value="22.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="6.8"/>
                    <measurement group_id="O2" value="23.6" spread="6.0"/>
                    <measurement group_id="O3" value="21.4" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="6.5"/>
                    <measurement group_id="O2" value="23.6" spread="5.9"/>
                    <measurement group_id="O3" value="22.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="8.3"/>
                    <measurement group_id="O2" value="24.5" spread="7.2"/>
                    <measurement group_id="O3" value="28.0" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="6.7"/>
                    <measurement group_id="O2" value="24.6" spread="6."/>
                    <measurement group_id="O3" value="31.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To test whether there were differences in the rate of change among groups</non_inferiority_desc>
            <p_value>0.867</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Size at 3 Months After Injection</title>
        <description>Tear size was evaluated by 3-point Likert scale using MRI. The 3months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.</description>
        <time_frame>baseline and 3 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Size at 3 Months After Injection</title>
          <description>Tear size was evaluated by 3-point Likert scale using MRI. The 3months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>stationary at month 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved at month 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>aggravated at month 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To test whether there were differences in the change of tear size among groups</non_inferiority_desc>
            <p_value>0.916</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Size at 12 Months After Injection</title>
        <description>Tear size was evaluated by 3-point Likert scale using MRI. The 12 months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.</description>
        <time_frame>baseline and12 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mesenchymal Stem Cell Group</title>
            <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.</description>
          </group>
          <group group_id="O2">
            <title>Active Control (Fibrin Glue) Group</title>
            <description>Received fibrin glue and normal saline.</description>
          </group>
          <group group_id="O3">
            <title>Control (Normal Saline )Group</title>
            <description>Received only normal saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Size at 12 Months After Injection</title>
          <description>Tear size was evaluated by 3-point Likert scale using MRI. The 12 months follow-up images were compared to the baseline image and graded either; improved, stationary, and aggravated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>stationary at month 12</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>improved at month 12</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>aggravated at month 12</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>To test whether there were differences in the change of tear size among groups</non_inferiority_desc>
            <p_value>0.892</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>All participants were asked the following open questions at every follow-up visit.&#xD;
How are you feeling?&#xD;
Have you had any kind of medical issue since the last visit?&#xD;
Have you had or currently on any medication since the last visit?&#xD;
Have you visited the emergency room or have been admitted to a hospital since the last visit?</desc>
      <group_list>
        <group group_id="E1">
          <title>Mesenchymal Stem Cell Group</title>
          <description>Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.&#xD;
allogenic adipose stem cell injection: Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.&#xD;
Eight participants were assigned and one declined to participate before the intervention.</description>
        </group>
        <group group_id="E2">
          <title>Active Control (Fibrin Glue) Group</title>
          <description>Received fibrin glue and normal saline.&#xD;
fibrin glue/normal saline injection: Total 1cc of fibin glue and normal saline mixture injection and range of motion exercise&#xD;
Eight participants were assigned and followed up throughout the study.</description>
        </group>
        <group group_id="E3">
          <title>Control (Normal Saline )Group</title>
          <description>Received only normal saline.&#xD;
normal saline injection: Total 1cc of normal saline injection and range of motion exercise&#xD;
Eight participants were assigned and followed up throughout the study except one who missed the last visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sun G. Chung</name_or_title>
      <organization>, Seoul National University Hospital</organization>
      <phone>+82-2-2072-2560</phone>
      <email>chung60611@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

